463 related articles for article (PubMed ID: 30249178)
1. Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.
Runcie K; Budman DR; John V; Seetharamu N
Mol Med; 2018 Sep; 24(1):50. PubMed ID: 30249178
[TBL] [Abstract][Full Text] [Related]
2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Hodgkin's disease with bispecific antibodies.
Hartmann F; Renner C; Jung W; Sahin U; Pfreundschuh M
Ann Oncol; 1996; 7 Suppl 4():143-6. PubMed ID: 8836426
[TBL] [Abstract][Full Text] [Related]
4. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
[TBL] [Abstract][Full Text] [Related]
5. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.
Tapia-Galisteo A; Compte M; Álvarez-Vallina L; Sanz L
Theranostics; 2023; 13(3):1028-1041. PubMed ID: 36793863
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2020; 15(4):272-292. PubMed ID: 32981510
[TBL] [Abstract][Full Text] [Related]
7. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
[TBL] [Abstract][Full Text] [Related]
8. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
9. [Development of monoclonal antibody therapy for malignant lymphoma].
Ogura M
Nihon Rinsho; 2002 Mar; 60(3):505-16. PubMed ID: 11904966
[TBL] [Abstract][Full Text] [Related]
10. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
Haagen IA
Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
[TBL] [Abstract][Full Text] [Related]
11. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
Liu X; Zhao J; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ
J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981
[TBL] [Abstract][Full Text] [Related]
13. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
14. Update on bi-specific monoclonal antibodies for blood cancers.
Shouse G
Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
[TBL] [Abstract][Full Text] [Related]
15. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology].
Igawa T
Yakugaku Zasshi; 2017; 137(7):831-836. PubMed ID: 28674296
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
Sikaria S; Aldoss I; Akhtari M
Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
[TBL] [Abstract][Full Text] [Related]
17. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic antibodies against cancer.
Adler MJ; Dimitrov DS
Hematol Oncol Clin North Am; 2012 Jun; 26(3):447-81, vii. PubMed ID: 22520975
[TBL] [Abstract][Full Text] [Related]
19. Bispecific antibody based therapeutics: Strengths and challenges.
Thakur A; Huang M; Lum LG
Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
[TBL] [Abstract][Full Text] [Related]
20. [Bispecific antibodies in onco-hematology: Applications and perspectives].
Barrière S; El-Ghazzi N; Garcia M; Guièze R
Bull Cancer; 2021 Oct; 108(10S):S195-S204. PubMed ID: 34920803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
